Florida-based Contract Development and Manufacturing Organisation (CDMO) GBI Biomanufacturing announced on Monday that it has entered into a manufacturing collaboration with Texas-based Allterum Therapeutics, a Fannin-Founded Company.

This partnership is intended to advance Allterum's lead candidate 4A10 into clinic. The product, a monoclonal antibody (mAb), is aimed at CD127, a receptor expressed by a broad variety of cancers.

Under the collaboration, GBI will produce 4A10 for Phase 1/2a clinical trials. Allterum's initial trial will focus on patients with acute lymphoblastic leukaemia (ALL), with subsequent expansion to trials in patients with other CD127-expressing haematological malignancies, including lymphomas and acute myeloid leukaemia.

Allterum's 4A10 development programme is supported by grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the National Cancer Institute (NCI) and the NCI Experimental Therapeutics Program (NExT). Invented at the NCI, the antibody is licensed exclusively to Allterum. Allterum has received Orphan Drug and Rare Pediatric Disease designations for ALL from the FDA.